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Pulmonary Nocardiosis and Aspergillosis closely mimic malignancy both clinically and radiolog-
ically. An aggressive workup is important since these infections are curable but potentially
fatal. We present an immunocompetent person in whom malignancy was strongly suspected
but actually had mixed infection with Nocardia and Aspergillus that responded to medical
therapy.
ª 2008 Elsevier Ltd. All rights reserved.Educational Aims:
 Infections such as Aspergillus and Nocardiosis, although
uncommon in immunocompetent persons, are not
unknown, and may coexist in the same person.
 Radiological appearance of infections may be confused
with malignant lesions.
 It is essential to attempt histological/cytological
diagnosis from such lesions in order to avoid the label
of malignancy while missing a treatable cause.11 26593006; fax: þ91 11
o.com (A. Mohan).
ll rights reserved.Introduction
Nocardia and Aspergillus species are well established
opportunistic pathogens in immunocompromised
persons. Pulmonary disease is the predominant clinical
presentation in infection by both organisms, and can be
fatal if untreated. They are usually considered in the
differential diagnosis of indolent pulmonary disease in
persons with immune compromise, along with other
actinomycetes (mycobacteria), and eumycetes (Crypto-
coccus neoformans, etc). However, they are uncommon
in immunocompetent persons, and concomitant infec-
tion with both even rarer. In these situations, the
clinician may be misled towards a malignant disorder.
We report one such rare occurrence of simultaneous
232 A. Mohan et al.infection with Nocardia and Aspergillus species in an
immunocompetent host.
Case report
A 54 year old male, security guard by occupation, pre-
sented to the medicine outpatient with multiple episodes
of hemoptysis since the last 20 years, which became more
frequent since 2 years. Each episode lasted for 7 to 10 days
with streaky blood tinged sputum interspersed with bouts
of significant hemoptysis of approximately 0.4e0.8 L of
blood loss. He also complained of left sided burning chest
pain. He gave no history of bleeding from any other site,
cough with expectoration, dyspnea, fever, loss of appetite
or weight. He denied any history of trauma to chest or
history suggestive of connective tissue disorder.
The patient was treated for pulmonary tuberculosis in
1984 for 18 months with good compliance. He left smoking
20 years back, never consumed alcohol or any other
addictives. He denies any history of hypertension or dia-
betes in the past. He has no history of exposure to organic
or inorganic dust or other noxious substances.
On initial evaluation, he was well preserved with mild
pallor and no other abnormalities on systemic examination.
Blood investigations revealed normal hemogram, hepatic
and renal profile, erythrocyte sedimentation rate, blood
sugar, and coagulation profile. Antinuclear antibodies, anti-
cytoplasmic antibodies, and HIV tests were negative. CD 4
and Immunoglobulins A, M, and G were within normal
limits. Sputum smear was negative for acid-fast bacilli or
malignant cells and culture did not reveal any bacteria or
fungi. The chest skiagram had bilateral scattered fibro-
calcific lesions, left upper lobe bronchiectasis, and a right
mid zone non-homogenous opacity. The contrast enhanced
computed tomogram of the chest done previously revealed
a soft tissue density mass with speculated margins and
satellite nodular specks in the right lower lobe suspicious of
a malignant lesion (Fig. 1A). Fiberoptic bronchoscopy
revealed normal airways and no intrabronchial growth.
Bronchoalveolar lavage fluid grew Pseudomonas species; no
acid-fast bacilli or malignant cells were seen.
A CT guided fine needle aspiration was performed from
the right lung lesion which revealed masses of fungal
hyphae admixed with fine filaments. Fungal hyphaeFigure 1 (A and B) Contrast enhanced CT scan of chest showing
lower lobe (A) and a crescent sign in the same lesion after one moshowed acute angled branching and septation (Fig. 2A).
These features were consistent with Aspergillus. The fine,
beaded, and branching filaments stained with silver stain
and were weakly acid-fast (Fig. 2B) suggestive of Nocardia.
The background showed dead fungal hypae with negligible
inflammation. The cytological diagnosis of Aspergilloma
with colonization by Nocardia species was made. A CT scan
done after one month showed a crescent sign in the
nodular lesion in the right upper lobe (Fig. 1B). The
patient was offered surgery to resect this lesion, but
declined.
Ketoconazole 400 mg solution was instilled intra-
bronchially into the right upper lobe, and the patient was
started on oral itraconazole 200 mg twice daily for two
months and cotrimoxazole (double strength) tablet for six
months. After one month of starting treatment, the
hemoptysis stopped and the patient has remained asymp-
tomatic after one year of follow-up. However, repeat CT
scan of the chest did not show any significant reduction in
the lung lesion.
Discussion
Pulmonary Nocardiosis is an uncommon but potentially
serious infection usually found in immunosuppressed
patients. Nocardia species are aerobic branching, filamen-
tous gram positive, weakly acid-fast bacteria that exist as
soil saprophytes. N. asteroides are the most frequent cause
of pulmonary infection in humans (85%).1 Aerosol route is
the major portal of entry and lung is the commonest site of
infection. The crucial role of cell mediated immunity has
been proven in experimental in vitro studies, hence
explaining the increased occurrence in immunocompro-
mised persons, such as HIV infection, alcoholism, chronic
obstructive pulmonary disease, malignancy, or prolonged
corticosteroid therapy.2e4 Patients present with fever,
chills, cough, sputum, weight loss, progressive dyspnea,
and occasionally hemoptysis. Radiological manifestations
include consolidation with/without cavitation, single or
multiple abscesses, nodules, or pleural involvement.5 Since
the clinic-radiological findings are relatively non-specific,
differential diagnosis includes several other bacterial,
fungal, and tubercular infections of the lung, as well as
malignancy. The diagnosis is based on the isolation ora spiculated mass-like lesion with satellite nodules in the right
nth (B).
Figure 2 (A) Mass of fungal hyphae and fine branching filaments (Papanicolaou 400). (B) Acid-fast filamentous bacteria (Ziehl-
Neelsen 1000).
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sputum, bronchoalveolar lavage, or percutaneous lung
aspirates. Nocardia is a slow growing organism that requires
prolonged incubation for at least 4e6 weeks. Antimicrobial
testing is a useful guide to therapy and is performed using
broth microdilution or BACTEC radiometric method.6,7
Most Nocardia isolates are sensitive to sulfonamides and
trimethoprim-sulfamethoxazole (TMP-SMX). The recom-
mended dose of TMP-SMX is 5e10 mg/kg (trimethoprim)
and 25e50 mg/kg (sulfamethoxazole) in two or four divided
doses. Therapy must be given for at least six months in
immunocompetent patients with pulmonary Nocardiosis,
and for twelve months in patients with cerebral involve-
ment, HIV or other immunodeficient states. Other paren-
teral drugs having activity against Nocardia include
Amikacin, Carbepenems and third generation cephalospo-
rins. Resolution of the disease is defined as eradication of
the Nocardia species along with clinical and radiological
improvement. However, some patients achieve predomi-
nantly clinical improvement, while radiological resolution
may be partial and delayed.
Pulmonary Aspergilloma is the commonest invasive
fungal infection in immunocompromised persons. A signifi-
cant percentage of patients with residual inactive tuber-
cular cavities may develop aspergillomas, commonest being
A. flavus.8 The spectrum of Aspergillosis ranges from simple
colonization (eg. Aspergilloma) to life threatening invasive
infection. Factors predisposing to infection include local
causes (COPD, pneumonia, pulmonary infarction, post-
influenza) as well as systemic causes (diabetes, bone
marrow and solid organ transplant recipients, HIV/AIDS,
chronic steroid therapy, chronic granulomatous diseases).
However, immunocompetent persons are not immune from
Aspergillosis and a similar spectrum of infection may occur
in these individuals, although at a much lesser frequency.
The clinical manifestation and severity depends on the
immunologic state of the patient and are similar to
pulmonary Nocardiosis. Patients may be asymptomatic or
present with varying degree of hemoptysis (upto 30%).
Radiological findings include nodules ranging from 1 to
3 cm which cavitate in 50% of patients. Cavitation usually
occurs after 10e14 days and produces a ‘crescent sign’ on
computed tomography. The ‘halo sign’ and the ‘air cres-
cent sign’ are relatively specific but poorly sensitive.9,10
Although serological methods such as detection of the
antigen galactomannan (cell wall glycoprotein) by ELISA,
EIA or immunoblot test (sensitivity and specificity >90%);and the polymerase chain reaction (PCR) for detection of
DNA and RNA copies are being increasingly used,11 the
cytological/histopathological demonstration of typical
septate hyphae or growth of Aspergillus in tissue speci-
mens remains the gold standard for a definitive diagnosis.
Symptomatic Aspergillomas may be treated by surgical
resection; however, the benefits should out weigh the risk
of surgery for patient at high risk of severe hemoptysis.
Although the long duration of hemoptysis in this patient
may be explained by the presence of old tubercular cavity
with Aspergilloma, the background history of smoking, and
a spiculated lung lesion initially seen on the CT scan
strongly suggested a possible malignant disorder. However,
fine needle aspiration cytology yielded multiple infections
with Aspergillus and Nocardia. The presence of such
concurrent pulmonary infection was reported once previ-
ously in an immunosuppressed patient due to long-term
steroid therapy; however, the current patient is probably
the first such report in an immunocompetent individual.
This clinical presentation emphasizes the importance of
keeping a broad differential diagnosis with rare non-
malignant disorders in mind even in persons with lung
lesions highly suspicious for malignancy.
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